Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

CRVO

CervoMed (CRVO)

CervoMed Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CRVO
DateTimeSourceHeadlineSymbolCompany
20/05/202422:00GlobeNewswire Inc.CervoMed to Appoint William Elder as Chief Financial OfficerNASDAQ:CRVOCervoMed Inc
15/05/202422:00GlobeNewswire Inc.CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:CRVOCervoMed Inc
01/04/202423:00GlobeNewswire Inc.CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdatesNASDAQ:CRVOCervoMed Inc
28/03/202423:30GlobeNewswire Inc.CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare InvestorsNASDAQ:CRVOCervoMed Inc
06/03/202400:00GlobeNewswire Inc.CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024NASDAQ:CRVOCervoMed Inc
22/02/202400:00GlobeNewswire Inc.CervoMed to Participate in the BIO CEO and Investor ConferenceNASDAQ:CRVOCervoMed Inc
13/02/202400:00GlobeNewswire Inc.CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy BodiesNASDAQ:CRVOCervoMed Inc
08/02/202400:30GlobeNewswire Inc.CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the BoardNASDAQ:CRVOCervoMed Inc
06/02/202400:00GlobeNewswire Inc.CervoMed to Participate in the Emerging Growth Conference 67NASDAQ:CRVOCervoMed Inc
06/01/202400:00GlobeNewswire Inc.CervoMed to Participate in the Emerging Growth Conference 66NASDAQ:CRVOCervoMed Inc
13/11/202323:00PR Newswire (US)CervoMed Reports Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:CRVOCervoMed Inc
26/10/202305:50PR Newswire (US)CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy BodiesNASDAQ:CRVOCervoMed Inc
24/10/202322:00PR Newswire (US)CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major DementiasNASDAQ:CRVOCervoMed Inc
18/10/202322:00PR Newswire (US)CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy BodiesNASDAQ:CRVOCervoMed Inc
05/10/202322:00PR Newswire (US)CervoMed to Present at the 2023 Roth Healthcare Opportunities ConferenceNASDAQ:CRVOCervoMed Inc
05/09/202321:00PR Newswire (US)CervoMed to Present at H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:CRVOCervoMed Inc
 Showing the most relevant articles for your search:NASDAQ:CRVO

Your Recent History

Delayed Upgrade Clock